Navigation Links
WuXi PharmaTech Files 2008 Annual Report on Form 20-F
Date:6/25/2009

SHANGHAI, June 25 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) today announced that it filed its annual report on Form 20-F for the year ended December 31, 2008 with the Securities and Exchange Commission. The annual report can be accessed on WuXi PharmaTech's website at http://www.wuxiapptec.com under the Investor Relations section. WuXi PharmaTech will provide a hard copy of its annual report on Form 20-F containing complete audited financial statements free of charge to its shareholders and ADS holders upon request. Requests should be directed to Ronald Aldridge, Director of Investor Relations, by email at ir@wuxiapptec.com .

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

    For more information, please contact:

    WuXi PharmaTech (Cayman) Inc.
     Ronald Aldridge (for investors)
     Director of Investor Relations
     Tel:   +1-201-585-2048
     Email: ir@wuxiapptec.com

     Stephanie Liu (for the media)
     Tel:   +86-21-5046-4362
     Email: pr@wuxiapptec.com

'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. WuXi PharmaTech Announces First-Quarter 2009 Results
2. WuXi PharmaTech Appoints Hao Zhou as Vice President of Finance
3. Pharmatech Oncology Launches New Data Management Business Unit
4. WuXi PharmaTech Schedules Fourth Quarter 2008 Earnings Release on Thursday, March 26, 2009
5. WuXi PharmaTech Announces CFO Benson Tsang to Leave Company; COO Edward Hu Named Acting CFO
6. WuXi PharmaTech Honored on the Deloitte Technology Fast 500 Asia Pacific 2008 List for the Fifth Consecutive Year
7. WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Leaves Board
8. WuXi PharmaTech to Present at 20th Annual Piper Jaffray Healthcare Conference
9. WuXi PharmaTech Expands Collaboration for Fully Integrated Services
10. WuXi PharmaTech Announces Second Quarter 2008 Results
11. WuXi PharmaTech (NYSE: WX) Appoints Mr. Steven M. Hutchins as VP of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... ... August 23, 2017 , ... Arizona Spine & ... that earned the designation of High Performing Hospitals by U.S. News & World Report ... a hospital was significantly better than the national average in a given procedure ...
(Date:8/23/2017)... , ... August 23, 2017 , ... Silicon Valley Hair ... a new blog archive organized month-by-month. The new rotation of archived blog posts can ... Area residents searching information about hair transplantation can review details online and then reach ...
(Date:8/23/2017)... , ... August 23, 2017 , ... ... the American Academy of Orthopaedic Surgeons , points out that therapeutic modalities ... from pain or injury. According to the report, a wider scope of physical ...
(Date:8/22/2017)... ... , ... The Women’s Choice Award, a growing platform that gives a voice ... Choice Award. The identification by women of an effective new migraine relief product ... women. In a survey taken by the Women’s Choice Award organization, nine out of ...
(Date:8/22/2017)... ... August 22, 2017 , ... Pivot Point Consulting, ... Zack Tisch as the firm’s new Consulting Services Executive. Mr. Tisch will oversee ... accounts, from assisting clients with initial vendor selection and pre-implementation planning through go-live ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... its Board of Directors has approved the payment of a ... 2017. The cash dividend ... October 27, 2017 to stockholders of record as of the ... dividends are subject to approval of the Board of Directors ...
(Date:8/7/2017)... DUBLIN , Aug. 7, 2017  Endo International ... has reached agreements to resolve virtually all known U.S. ... in discussions to resolve the known remaining U.S. claims ... installment payments beginning in the fourth quarter of 2017 ... part of its second quarter 2017 results, the Company ...
Breaking Medicine Technology: